---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-136728"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:25:13.972580+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# UroGen Q1 net loss $32.3M; JELMYTO revenue up 10% to $18.8M; UGN-102 NDA on track

## Summary
- Net loss $32.3M ($0.97/share) vs $30.2M ($1.30) in Q1 2023; JELMYTO revenue $18.8M, +10% YoY.
- FY2024 guidance reiterated: JELMYTO revenue $95-102M; operating expenses $175-185M.
- UGN-102 rolling NDA submission to complete Q3 2024; ENVISION 12-month DOR data event June 13.
- IND accepted for UGN-103; Phase 3 in LG-IR-NMIBC planned for 2024.
- Cash $164.5M; OLYMPUS post-hoc shows JELMYTO median duration of response 47.8 months.

## SEC filing metadata
- accession: 0001193125-24-136728
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/0001193125-24-136728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/d804276d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-136728
- JSON: https://secwatch.observer/filing/0001193125-24-136728.json
- Plain text: https://secwatch.observer/filing/0001193125-24-136728.txt

## Key facts
- Earnings Releases
  UroGen Pharma Ltd. reported the first quarter ended March 31, 2024 results: revenue $18.8 million, net income net loss of $32.3 million or ($0.97) per basic and diluted share, EPS ($0.97) per basic and diluted share. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $18.8 million
  - Net income: net loss of $32.3 million or ($0.97) per basic and diluted share
  - EPS: ($0.97) per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: • Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free periods more than 47.8 months in LG-UTUC • JELMYTO ® demonstrated continued growth with net product sales of $18.8 million in Q1, compared with $17.2 million in Q1 2023 representing ~10% YoY growth • IND accepted for UGN-103, next-generation novel mitomycin-based formulation of UGN-102 to treat
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524136728/0001193125-24-136728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.